Drug Information

Drug General Information
Drug ID
D0Z8KS
Former ID
DNCL002222
Drug Name
Zanolimumab
Drug Type
Antibody
Indication Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] Phase 3 [521655]
Company
Emergent BioSolutions
CAS Number
CAS 652153-01-0
Target and Pathway
Target(s) T-cell surface glycoprotein CD4 Target Info [528688]
KEGG Pathway Cell adhesion molecules (CAMs)
Antigen processing and presentation
Hematopoietic cell lineage
T cell receptor signaling pathway
Primary immunodeficiency
NetPath Pathway Leptin Signaling Pathway
Pathway Interaction Database TCR signaling in na&#xef
IL12-mediated signaling events
CXCR4-mediated signaling events
C-MYB transcription factor network
IL23-mediated signaling events
Arf1 pathway
Notch-mediated HES/HEY network
IL12 signaling mediated by STAT4
Reactome Binding and entry of HIV virion
Phosphorylation of CD3 and TCR zeta chains
Translocation of ZAP-70 to Immunological synapse
Generation of second messenger molecules
PD-1 signaling
WikiPathways TCR Signaling Pathway
Cytokines and Inflammatory Response
Host Interactions of HIV factors
Defensins
HIV Life Cycle
TCR signaling
Costimulation by the CD28 family
References
Ref 521655ClinicalTrials.gov (NCT00127881) Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome. U.S. National Institutes of Health.
Ref 528688Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62. Epub 2007 Feb 20.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.